Janux Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(48,778) | $(46,535) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,548 | 1,424 |
| Stock-based compensation | 26,769 | 15,522 |
| Accretion of discounts on investments, net | (7,658) | (5,627) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (3,077) | (60) |
| Other long-term assets | (314) | (924) |
| Accounts payable | 25 | (50) |
| Accrued expenses | 6,060 | (1,104) |
| Deferred revenue | (1,705) | (3,979) |
| Operating lease right-of-use assets and liabilities, net | 41 | 659 |
| Net cash used in operating activities | (27,089) | (40,674) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (317) | (1,335) |
| Purchases of short-term investments | (446,545) | (284,232) |
| Maturities of short-term investments | 154,915 | 233,250 |
| Net cash used in investing activities | (291,947) | (52,317) |
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options and employee stock purchase plan | 6,526 | 2,187 |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | 320,059 | 56,530 |
| Net cash provided by financing activities | 326,585 | 58,717 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 7,549 | (34,274) |
| Cash, cash equivalents and restricted cash – beginning of year | 20,021 | 52,242 |
| Cash, cash equivalents and restricted cash – end of period | $27,570 | $17,968 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Unpaid property and equipment | $42 | $430 |
| Vesting of restricted common stock | $13 | $144 |
| Unrealized gain on available-for-sale securities, net | $7,166 | $360 |
Notes to Unaudited Condensed Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.